Drug Trial Radar · NCT03910361
Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases
Last checked: Nov 20, 2026Latest source record: Apr 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Apr 12, 2019
Primary completion
Jul 2, 2020
Study completion Jul 2, 2020
Sponsor
- Lead sponsor
- Dong-A ST Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver diseases
Conditions
- Type2 Diabetes
- Non-Alcoholic Fatty Liver Disease
Interventions
EvogliptinDrug
evogliptin 5mg tablet qd + placebo tablet matching to pioglitazone 15mg qd
PioglitazoneDrug
pioglitazone 15mg tablet qd + placebo tablet matching to evogliptin 5mg qd
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes from baseline intrahepatic fat (%)Time frame: 24 weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Samsung Medical Center
Changwon, South Korea
Soonchunhyang University Hospital
Cheonan, South Korea
Keimyung Dongsan University Medical Center
Daegu, South Korea
Hanyang University Guri Hospital
Guri-si, South Korea
Catholic University of Seoul ST.Mary's Hospital
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.